Navigation Links
Federal Laws Debut this Week to Expose Financial Ties Between Medical Companies and Doctors, Parker Waichman LLP Notes
Date:7/30/2013

New York, New York (PRWEB) July 30, 2013

Parker Waichman LLP, a national law firm dedicated to protecting the rights of victims injured by defective drugs and medical devices, comments on the debut of the Physician Payment Sunshine Act provision of the Affordable Care Act, which is being implemented this week to expose cases of allegedly fraudulent financial relationships between doctors and pharmaceutical and medical device companies, as detailed in the Feb. 8, 2013, Federal Register. It will do so by having the device makers and drug companies collect data on their financial relationships with doctors, researchers and teaching hospitals.

The provision resulted from six years of legislative and regulatory battles fought over whether some drug and medical device companies were gaining inappropriate influence, according to a July 28 (Minneapolis) Star Tribune report.

Minnesota is home to the multibillion-dollar medical technology sector, which believes the new federal mandate is cause for optimism, according to the article. Many companies are banking on these new regulations to quell any concern about alleged fraudulence.

Medtronic, one of the world’s largest device makers, is a recent example that highlights the medical device industry’s lingering concerns over doctor payments, the article noted. The U.S. Senate Finance Committee alleged in October that Medtronic had heavily influence medical-journal reports regarding its spinal fusion product, Infuse, the Star Tribune noted. The committee questioned whether doctors who supervised the studies had downplayed Infuse’s risks while shining a spotlight on the product’s benefits –allegedly doing so to the tune of $210 million in royalties and consulting fees paid to them from Medtronic over a 15-year period.

“We believe patients have the right to know things like whether their physician is getting paid a huge sum of money from the pharmaceutical company or medical device maker that makes the pill or medical device that the doctor prescribes for them,” said Parker Waichman LLP. “It should be quite obvious that there is potential for conflicts of interest in such instances.”

Starting Thursday, drug and medical companies must track transactions with doctors, teaching hospitals and other health-related businesses. The first round of data must be submitted to federal regulators by the end of the year; it is slated to be made public by next September. The new law comes with fines of up to $1.15 million for companies that fail to disclose. It also requires senior managers to sign off on the data, making them personally accountable.

Parker Waichman LLP is currently offering free legal consultations to victims of Medtronic Infuse Bone Graft Injuries. If you or a loved one suffered a serious complication or injury after receiving Medtronic Infuse, please contact their office by visiting the firm's Medtronic Infuse injury page at yourlawyer.com. Free case evaluations are also available by calling 1-800-LAW-INFO (1-800-529-4636).

Contact:    
Parker Waichman LLP
Gary Falkowitz, Managing Attorney
(800) LAW-INFO
(800) 529-4636
http://www.yourlawyer.com

Read the full story at http://www.prweb.com/releases/federal_disclosure_law/medtronic_infuse/prweb10979754.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Mesh Lawsuit News: Bernstein Liebhard LLP Notes New Order in Federal Ethicon Vaginal Mesh Lawsuits
2. New Update on Alleged Transvaginal Mesh Complications Lawsuits: First Federal Trial Involving Allegations of Serious Side Effects from C.R. Bard Mesh Scheduled to Begin
3. Mesh Lawsuit – Bellwether Cases Selected in Federal Litigation Underway for Ethicon Transvaginal Mesh Lawsuits, Bernstein Liebhard LLP Reports
4. Actos Lawsuit – Status Conference Convened in Federal Actos Bladder Cancer Multidistrict Litigation, Bernstein Liebhard LLP Reports
5. Byetta Lawsuit - Claims Move Forward, as Panel Considers Consolidation of Federal Claims Involving Byetta and Similar Diabetes Drugs, Bernstein Liebhard LLP Reports
6. Mesh Lawsuit - First Bellwether Trial in Federal C.R. Bard Transvaginal Mesh Litigation Set to Begin Monday, Bernstein Liebhard LLP Reports
7. Pradaxa Lawsuit News: Bernstein Liebhard LLP Reports on Latest Status Conference in Federal Pradaxa Bleeding Litigation
8. Actos Bladder Cancer Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order in Federal Actos Litigation
9. GranuFlo Lawsuits Move Forward, as Bernstein Liebhard Notes Issuance of New Order in Federal GranuFlo Recall Litigation
10. Transvaginal Mesh Lawsuits Move Forward in Federal Litigations with Issuance of New Case Management Order, Bernstein Liebhard LLP Reports
11. Actos Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Upcoming Status Conference in Federal Actos Bladder Cancer Litigation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... ... 30, 2017 , ... According to the American Society of Plastic Surgeons (ASPS), ... the top 5 most popular minimally-invasive cosmetic procedures in the country. With summer close, ... over the next 8-10 weeks. For anyone considering a hair removal procedure, there are ...
(Date:3/30/2017)... ... March 30, 2017 , ... AudioEducator, a ... “ Preventing Hospital Readmissions Through Discharge Planning ” with noted expert Sue Dill ... This conference discusses strategies to prevent readmissions in light of the most recent ...
(Date:3/29/2017)... , ... March 29, 2017 , ... ... women’s professional squash, announced it has enlisted New York City-based sports and entertainment ... will develop and procure sponsorship opportunities for the Professional Squash Association (PSA), which ...
(Date:3/29/2017)... Petersburg, FL (PRWEB) , ... March 30, 2017 , ... ... called the "Spice of Life" or "Wonder Spice", it has been used for thousands ... use in the East," says Heshelow, author of " Turmeric: How to Use it ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... provides insight into the challenges employers face in trying to balance both short-term ... employee benefits programs? Adding to the growing complexity, companies are finding that ...
Breaking Medicine News(10 mins):
(Date:3/30/2017)... 30, 2017  Akcea Therapeutics, a subsidiary of Ionis ... a Phase 2b dose-ranging study of AKCEA-APO(a)-L Rx ... goal of the study is to determine the dose ... in a planned Phase 3 cardiovascular outcome study. ... strategic collaboration with Novartis to develop and commercialize drugs ...
(Date:3/29/2017)... March 29, 2017  Bodycad announced today that ... (FDA) 510(k) clearance for its Bodycad Unicompartmental Knee ... personalized orthopaedic restoration. Bodycad is the first Canadian ... reconstruction implant system. Bodycad,s revolutionary ... restoration of the patient,s unique anatomical features and ...
(Date:3/29/2017)... , March 29, 2017 Avelas Biosciences, Inc., a ... diagnosis through treatment, today announced that Carmine N. Stengone , ... company at the Needham & Company 16 th Annual Healthcare ... a.m. PDT) at the Westin Grand Central Hotel in ... ...
Breaking Medicine Technology: